IL22

Across TCGA pan-cancer cohorts, IL22 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IL22 data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IL22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL22 expression acts as an unfavorable survival marker.

HNSC, LUAD, and BLCA are the cancer types where IL22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.751	<.001	48	view →
LUAD	OS	Median	All	0.290	0.813	<.001	27	view →
BLCA	DFS	Median	All	0.159	0.625	.016	15	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IL22–HNSC (OS)

Open the HNSC breakdown →